The therapeutic relevance of Trachisan is in situations involving certain distressing symptoms associated with acute irritations of the mouth and throat. The primary benefit is associated with symptomatic relief across key domains, including symptoms related to inflammatory or irritative states.

Trachisan is commonly used across conditions presenting with acute episodes, which involve symptoms related to physical discomfort, such as pharyngitis, tonsillitis, stomatitis, and gingivitis. The medication is relevant for managing symptoms that interfere with daily comfort, including throat pain, a burning sensation, and difficulty swallowing. It is also applicable in settings that involve acute or disruptive symptom patterns, such as post-operative discomfort following minor procedures like tooth extraction.

It assists with maintaining functional stability by addressing both localized discomfort and related irritative states, and contributes to easing the overall symptom load during periods where short-term symptomatic assistance is needed.

---

Symptom Management Summary

Domain	Symptom Targeted	Benefit Provided
Oropharyngeal	Throat pain, difficulty swallowing, burning sensation	Supports patient coping by easing distress
Oral Mucosa	Stomatitis, Gingivitis, Inflammation	Assists with maintaining functional stability
Context	Post-operative localized pain	Contributes to easing overall symptom load

Regulatory References

1. Public Assessment Report - Geneesmiddeleninformatiebank

Official Regulatory Eligibility Profile

This information describes who can and cannot use this medicine based strictly on official regulatory labeling from health authorities.

Contraindications (Must NOT Use)

The only absolute contraindication is a known hypersensitivity (allergy) to Chlorhexidine, Lidocaine, or any of the inactive ingredients (excipients) in the formulation. Use is strictly prohibited for these individuals.

Age-Related Eligibility Rules

• Children: Use of the lozenge or oral rinse formulation is generally not recommended or approved for children below a specified age (e.g., typically under 12 years old, though this can vary by specific product label). The safety and effectiveness of the medicine have often not been established in the younger pediatric population.
• Adults: Adults who do not have a contraindication are generally eligible for use.

Pregnancy and Lactation Eligibility Status

• Pregnancy: The medicine should be used during pregnancy only if clearly needed. This restriction is due to a lack of adequate, controlled studies in pregnant women, necessitating a professional assessment of the necessity of the drug.
• Lactation (Breastfeeding): Caution should be exercised when administered to nursing women, as it is not conclusively known whether the drug is excreted in human milk.

---

Summary of Official Constraints

Eligibility is defined by the absence of allergy and specific age limitations. Regulatory documents classify the medicine as contraindicated for allergic individuals and classify its use in younger children as 'not established,' placing constraints on who can safely and officially use the drug.

Interactions with other medicines and products

Official regulatory information for Trachisan lozenges highlights interactions primarily related to the localized, chemical properties of its active ingredients, particularly Chlorhexidine, due to the product’s minimal systemic absorption.

Property	Details
Pharmacodynamic Interaction	Local chemical antagonism/inactivation of the cationic agent Chlorhexidine by anionic substances.
Interacting Substances	Anionic Compounds including anionic detergents and anionic soaps; also present in some oral hygiene products (e.g., toothpastes).
Systemic Interaction Risk	None documented; minimal systemic exposure prevents listing of clinically relevant systemic metabolic (CYP enzyme) or transporter-mediated interactions.

---

Regulatory Interaction Constraints

The primary officially documented interaction involves the reduction or inactivation of the antiseptic effect of Chlorhexidine when co-administered with anionic substances. This chemical antagonism results in a mandatory constraint outlined in regulatory documents: the concurrent use is restricted or prohibited with products containing anionic agents. This restriction ensures that the local antiseptic efficacy of the lozenge is maintained at the application site. Regulatory documentation for the lozenge formulation does not list any specific population-dependent interaction considerations or timing requirements for systemic medicines.

How Trachisan (+Chlorhexidin) Works

The drug’s physiological effect is achieved through the actions of its two components, which target separate mechanistic domains: peripheral nerve conduction and microbial cellular integrity.

---

Local Nerve Signal Blockade

The anesthetic component operates locally on the membranes of peripheral sensory nerves by functioning as a sodium channel blocker. This mechanism prevents the necessary rapid influx of sodium ions across the membrane , thereby halting the generation of nerve action potentials. The resulting physiological consequence is the reversible inhibition of peripheral nerve action potential propagation at the application site.

---

Microbial Cell Integrity Disruption

The antimicrobial component acts by disrupting microbial cell structure. Its positively charged molecule strongly binds to the negatively charged components on the microbial cell surfaces, which ultimately breaches the cell wall and membrane integrity . This breach leads to internal component leakage and coagulation. This mechanism supports the inhibition of microbial proliferation and cell viability against local bacteria and fungi.

How Trachisan (+Chlorhexidin) is Used

Trachisan is intended for oromucosal administration, meaning the lozenge is applied topically to the tissues of the mouth and throat to achieve a highly localized effect. This method ensures the active components are concentrated at the site of application. Adherence to the instructions for use establishes the standardized protocol for administration.

---

Standard Dosing and Administration

The standard pattern of use for adults and adolescents (age 12 and over) involves slowly dissolving one lozenge per administration in the mouth. It is critical that the lozenge is not chewed or swallowed whole as this bypasses the intended slow-release topical mechanism. To maintain the local presence of the ingredients, a time-based restriction applies: users must avoid eating or drinking for approximately 30 minutes after the lozenge has fully dissolved.

The lozenge is typically administered at a minimum interval of two hours, with the maximum allowable daily dose strictly limited to eight lozenges in a 24-hour period.

---

Duration and Age-Specific Use

Usage is intended for short-term symptomatic assistance. Guidance advises continuing administration for an additional two to three days after symptoms have disappeared to support a lasting resolution. However, continuous self-managed use should not exceed 10 days.

Specific dosage modifications are implemented for pediatric use. The formulation is not recommended for children under six years of age. For children age 6 years, the unit dose remains one lozenge, but the maximum daily limit is restricted to six lozenges. Due to the local anesthetic effect, children under 12 must use the product with caution to minimize the potential risk of aspiration.

Research Evidence / Overview of Studies

Summary of Key Findings

Research has explored whether the combination of tyrothricin, chlorhexidine, and lidocaine could be beneficial for patients with inflammatory and infectious diseases of the mouth and pharynx, such as pharyngitis. Research focused on the potential effects of the triple combination, utilizing tyrothricin for its local antibacterial activity, chlorhexidine for its antiseptic properties against Gram-positive, Gram-negative bacteria, and some fungi, and lidocaine as a local anesthetic to address discomfort.

Studies investigated whether the combination was associated with a reduction of subjective symptoms, including sore throat and difficulty swallowing, over short-term treatment periods.

---

Detailed Study Analysis

Clinical Trial Findings

Findings suggesting potential symptom relief were reported in clinical studies involving patients with acute inflammatory diseases of the oral cavity and pharynx. These trials evaluated whether the Trachisan combination was associated with a change in subjective symptom scores compared to baseline or control.

• Symptom Relief Evaluation: In certain evaluations, study data indicated a reported decrease in the intensity of sore throat within the first few hours of application, suggesting a potential contribution from the local anesthetic component. Further, studies evaluated the reported tolerability of the combination in adult and older pediatric populations.
• Comparative Data: Research examined whether the use of the combination was associated with improved outcomes when compared against other common treatments for throat inflammation.

Safety and Tolerability Data

Across the clinical reviews, the most frequently reported events associated with the use of the combination included transient effects such as temporary taste disturbance, minor local irritation, or temporary numbness of the tongue. During the trials, no serious adverse events were reported for the combination, but long-term safety data remains under review. Future studies are needed to explore the long-term potential of this local treatment beyond acute symptom management.

Key Studies & References

1. Tyrothricin, chlorhexidine, and lidocaine in the treatment of acute pharyngitis and other oropharyngeal infections: A systematic review
2. Clinical Practice Guideline: Pharyngitis (Sore Throat)

Common questions about Trachisan (+Chlorhexidin) (FAQ)

Q: Is Trachisan the same as a regular throat lozenge?

Regulatory documents classify this preparation as a specialized combination that contains three active ingredients: Tyrothricin (a local antibiotic), Chlorhexidine (an antiseptic), and Lidocaine (a local anesthetic). Because of this triad of components, official classification places it within the category of a local anti-infective and local anesthetic combination, which is different from many single-component remedies.

Q: Is Trachisan suitable for people who wear dentures?

Official warnings note that the product carries the potential for brown staining on teeth and dental work, including dentures. This is more likely to occur if the product is used for a prolonged period. Given this, it is important to note the potential for temporary staining.

Q: Are there any known issues with taking Trachisan while on antibiotics?

The official product information states that the systemic absorption of the lozenge's ingredients is minimal. As a result, the regulatory label does not list clinically relevant drug-to-drug interactions with systemic antibiotics taken by mouth or injection. The main documented constraint involves local chemical antagonism with anionic substances, such as some toothpastes.

Q: Does Trachisan affect the taste of food?

Official adverse reaction listings report that taste disturbance (also known as dysgeusia) is a potential, temporary side effect. This indicates the medicine may temporarily affect taste perception while the ingredients are active at the application site.

Q: Is Trachisan considered safe for use by older adults?

Regulatory documents apply the standard adult dosage to older adults who do not have a known allergy or contraindication to the ingredients. Warnings concerning the local anesthetic effect and potential aspiration are primarily directed at children under 12, which suggests no distinct age-related restrictions are noted for adults, beyond the general use precautions.

Q: What happens if you accidentally swallow a lot of Trachisan?

The lozenge is designed for local action, and official information emphasizes that the systemic absorption is minimal. However, official safety warnings for products containing lidocaine advise that ingestion should be avoided, especially in children, and regulatory documents emphasize that exceeding the recommended daily dosage carries associated risks.

Q: Are there specific substances or foods to avoid when using Trachisan?

Official documents describe a constraint to avoid eating or drinking for approximately 30 minutes after the lozenge has dissolved. Furthermore, concurrent use with anionic compounds, such as anionic soaps, detergents, and certain oral hygiene products, is restricted because they can chemically reduce the antiseptic's effectiveness.

Q: Is Trachisan available over-the-counter or does it require a prescription?

In many regions where it is approved by regulatory bodies, the product is classified as an Over-The-Counter (OTC) or non-prescription medicine.

Q: Does Trachisan contain sugar or artificial sweeteners?

The official regulatory label specifies that the product is formulated to be sugar-free (sucrose-free). The excipient list confirms the presence of sorbitol, which is a sugar substitute.

Q: Do official sources describe any precautions for people with liver or kidney issues when using Trachisan?

Since the product is designed for minimal systemic absorption, the lozenge label does not typically list specific restrictions for mild liver or kidney impairment. However, official warnings for similar products with local anesthetic components suggest that caution may be considered in cases of significant hepatic (liver) or renal (kidney) impairment due to the potential for altered metabolism, though this lozenge has minimal systemic absorption.

Q: Are there different forms of Trachisan, like a liquid or spray, besides the lozenges?

The officially documented product is consistently defined as a lozenge (tablet) form for oromucosal use.

Q: Can Trachisan be used for mouth ulcers or just the throat?

Official indications include local treatment of inflammation and infection of the oral mucosa, gums, and throat. The defined scope covers the entire mouth cavity, but specific diagnoses like mouth ulcers are not explicitly listed.

Q: Are there any warnings about using Trachisan before a medical procedure?

Regulatory safety information, particularly concerning Chlorhexidine, advises that healthcare professionals should inquire about a patient's prior allergies before any procedure where chlorhexidine may be used. The warning to inquire about prior allergies is a regulatory constraint linked to the presence of Chlorhexidine in the formulation.

Q: What research is available on the combination of Chlorhexidine and Lidocaine in a lozenge?

The primary clinical evidence documented in regulatory summaries covers the effects of the full triple combination of Tyrothricin, Chlorhexidine, and Lidocaine. Studies have examined how this combination may potentially reduce discomfort and manage microbial presence in inflammatory conditions of the mouth and pharynx.

Q: Why is Trachisan often mentioned in discussions about tonsillitis?

Official regulatory indications for the product explicitly list tonsillitis (or angina) as one of the infectious and inflammatory diseases of the oral cavity and throat that the product is intended to treat locally.

Q: Can Trachisan be used by people with diabetes?

Official product information notes that the lozenge is sugar-free (sucrose-free) and contains sorbitol as a sweetener. This information is provided to help individuals, including those with diabetes, manage their intake.

Q: What kind of general expectations should I have about the duration of Trachisan's effects?

The anesthetic component is described as a rapid-acting local nerve blocker, suggesting a quick onset of relief. The regulatory-defined minimum interval between doses is strictly two hours, which serves as a general boundary for the product's localized duration of action before re-administration.

Q: What should I do if I notice a change in the color of my tongue after using Trachisan?

Official labels document that brown staining on the tongue is a known side effect of the product. Official product information notes this staining is often described as a reversible effect that typically resolves upon discontinuation of the product.

Q: Do official documents mention any potential for long-term side effects from Trachisan?

Official safety warnings indicate that side effects, particularly the brown staining on oral tissues, are more likely to occur with prolonged use. Regulatory guidance strictly limits continuous self-managed use to a maximum of 10 days.

Q: Is it normal to feel a slight tingling sensation after using Trachisan?

While the specific term 'tingling' is not always used, regulatory labels list side effects such as temporary numbness and local sensations like a burning feeling or irritation in the mouth or throat. These local nerve and sensation effects are clinically related to the feeling of tingling.

Q: How long after using Trachisan can I brush my teeth?

A waiting period is necessary before using oral hygiene products, such as toothpaste, that contain anionic compounds. This is required to help avoid the chemical inactivation of the antiseptic component.

Official Storage and Disposal Requirements

Storage of Trachisan lozenges must comply with regulatory requirements to ensure product stability and safety. The product must not be stored above 25 °C and it is strictly required to not refrigerate or freeze the lozenges. They must be stored in the original package to protect the contents from moisture, thereby supporting the established 3-year shelf life.

Consistent with child safety regulations, the medicine must be stored out of the sight and reach of children.

For disposal, unused or expired lozenges must not be discarded via wastewater or mixed with household waste. The official instruction is to consult a pharmacist or local regulatory authority for proper disposal, ensuring the medicine is handled in accordance with local requirements.